ICD-10 Coding for Acute Myelogenous Leukemia(C91.0, C92.0, C92.00)
Explore comprehensive ICD-10 coding guidelines for acute myelogenous leukemia, including remission status and documentation requirements.
Complete code families applicable to Acute Myelogenous Leukemia
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C92.00 | Acute myeloblastic leukemia not having achieved remission | Use when AML is newly diagnosed and not in remission. |
|
| C92.01 | Acute myeloblastic leukemia, in remission | Use when AML is in complete remission as per clinical criteria. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutAcute Myelogenous Leukemia
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Acute Myelogenous Leukemia.
Failing to update remission status
Impact
Clinical: May lead to inappropriate treatment decisions., Regulatory: Non-compliance with coding standards., Financial: Potential for incorrect billing and reimbursement.
Mitigation
Regularly review and update patient records, Ensure clinical criteria are documented
Using unspecified codes for AML
Impact
Reimbursement: Unspecified codes may lead to lower reimbursement rates., Compliance: Increases risk of audit due to lack of specificity., Data Quality: Reduces the accuracy of clinical data for research and treatment planning.
Mitigation
Always specify the subtype and remission status of AML.
Remission Status Documentation
Impact
Inadequate documentation of remission status can trigger audits.
Mitigation
Ensure all remission criteria are clearly documented in patient records.